公开(公告)号：US20160287717A1

公开(公告)日：2016-10-06

申请号：US15023093

申请日：2014-09-18

Applicant: STC.UNM ,  SANDIA CORPORATION

Inventor： Charles Jeffrey Brinker ,  Jason TOWNSON ,  Yu-Shen LIN ,  Paul N. DURFEE

IPC: A61K47/48 ,  A61K9/51

CPC classification number: A61K47/6929 ,  A61K9/0019 ,  A61K9/1271 ,  A61K9/5115 ,  A61K9/5146 ,  A61K47/02 ,  A61K47/59 ,  A61K47/60 ,  A61K47/6923

Abstract: In one aspect, the invention provides mesoporous silica nanoparticles (MSNPs), monodisperse populations of MSNPs and related protocells which exhibit single cell binding specificity to the substantial exclusion of non-targeted cells. For example, MSNPs and protocells of the invention may be used to target specific delivery of therapeutic agents to cancer cells or to specific blood vessel types (e.g. in the arterial, venous and/or capillary vessels or any combination of vessels). Related protocells, pharmaceutical compositions and therapeutic and diagnostic methods are also provided.

Abstract translation: 一方面，本发明提供介孔二氧化硅纳米颗粒（MSNP），MSNP的单分散群体和相关的原细胞，其显示出对非靶向细胞的实质排除的单细胞结合特异性。 例如，本发明的MSNPs和原细胞可用于靶向治疗剂到癌细胞或特定血管类型（例如在动脉，静脉和/或毛细血管或血管的任何组合中）的特异性递送。 还提供了相关的原细胞，药物组合物和治疗和诊断方法。